Business

Skyepharma says that it will begin developing a COPD therapy based on Pulmagen’s ICS “re-sensitization” technology (SKP-2075) by the end of 2014 after acquiring the IP and global rights to the Theocort platform from Pulmagen.… Read more . . .

Insmed Incorporated is offering 8.9 million shares of common stock at $11.25 per share, with expected net proceeds of $94 million to go toward continued development of Arikayce liposomal amikacin for inhalation. The company recently… Read more . . .

Sanofi will pay MannKind $150 million upfront and milestone payments of up to $775 million for an exclusive development and commercialization license for Afrezza insulin inhalation powder, the companies have announced. The companies will split… Read more . . .

Alexza Pharmaceuticals partner Grupo Ferrer has launched its Adasuve loxapine inhalation powder in Guatemala, Alexza has announced. The approval in Guatemala is the first that Ferrer has obtained for Adasuve outside of Europe. Ferrer is… Read more . . .

Aegis Therapeutics has announced the availability of “an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug.” Aegis’s intranasal product would be the only non-injectable formulation of exenatide,… Read more . . .

According to OptiNose, the company has completed a Series C-1 round of financing that will support development of its second product, OPN-375 intranasal fluticasone. The company, along with partner Avanir, submitted an NDA for its… Read more . . .

AstraZeneca will pay $875 million initially, plus up to an additional $1.22 billion to acquire development and commercialization rights to Almirall’s entire respiratory drug business. Almirall’s respiratory products include the Eklira/Bretaris/Tudorza aclidinium DPI, an aclidinium/formoterol… Read more . . .